{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Sees Surge in Call Option Activity Amid Bullish Momentum
Sun Pharmaceutical Industries Ltd (SUNPHARMA) has witnessed a notable surge in call option trading, signalling increased bullish sentiment among investors. The pharmaceutical giant’s stock has outperformed its sector peers, supported by strong price action and significant open interest in near-term call options, particularly at the ₹1700 strike price expiring on 24 February 2026.
Sun Pharmaceutical Industries Ltd Hits Intraday High with Strong 3.42% Surge
Sun Pharmaceutical Industries Ltd demonstrated robust intraday performance on 3 Feb 2026, surging to an intraday high of Rs 1,725, marking a 5.9% rise from the previous close. The stock outpaced the broader Pharmaceuticals & Biotechnology sector and the Sensex, reflecting strong trading momentum amid a mixed market backdrop.
Sun Pharmaceutical Industries Ltd: Navigating Nifty 50 Membership and Market Dynamics
Sun Pharmaceutical Industries Ltd, a stalwart in the Pharmaceuticals & Biotechnology sector, continues to demonstrate resilience amid evolving market dynamics. Its status as a Nifty 50 constituent underscores its significance in India’s equity landscape, while recent institutional holding changes and benchmark influences have shaped investor sentiment and stock performance.
Sun Pharmaceutical Industries Ltd Technical Momentum Shifts Amid Mixed Market Signals
Sun Pharmaceutical Industries Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of technical indicators. Despite a modest day gain of 0.95%, the stock’s broader technical signals suggest a cautious outlook amid mixed momentum cues.
Has Sun Pharmaceutical Industries Ltd declared dividend?
Yes, Sun Pharmaceutical Industries Ltd has declared a dividend of 1100% (₹5.5 per share), with an ex-date of February 5, 2026. While recent short-term returns have been negative, the company has shown strong growth over longer periods.
Sun Pharmaceutical Sees Heavy Put Option Activity Amid Bearish Sentiment
Sun Pharmaceutical Industries Ltd has emerged as the most active stock in put options trading, signalling a notable shift in market sentiment. With significant volumes concentrated at the ₹1600 strike price for the 24 February 2026 expiry, investors appear to be positioning for downside risk or hedging against potential volatility in the pharmaceutical giant’s shares.
Sun Pharmaceutical Industries Ltd: Navigating Nifty 50 Membership Amid Mixed Performance
Sun Pharmaceutical Industries Ltd, a key constituent of the Nifty 50 index, is currently facing a challenging market environment marked by underperformance relative to its sector and benchmark indices. Despite its significant market capitalisation and longstanding presence in the Pharmaceuticals & Biotechnology sector, recent shifts in institutional holdings and valuation metrics have prompted a reassessment of its investment appeal.
Are Sun Pharmaceutical Industries Ltd latest results good or bad?
Sun Pharmaceutical Industries Ltd's latest results are strong, with record net sales of ₹15,520.54 crores and a net profit of ₹3,368.81 crores, reflecting significant year-on-year growth and improved operational efficiency. The company's solid financial position and healthy return on equity indicate robust performance, despite some market valuation adjustments.
Sun Pharma Q3 FY26: Strong Quarter Marred by Valuation Concerns
Sun Pharmaceutical Industries Ltd., India's largest pharmaceutical company and the fourth-largest global specialty generic player, delivered an impressive third quarter for FY2026, posting consolidated net profit of ₹3,368.81 crores—an 8.05% sequential increase and 16.03% year-on-year growth. With a market capitalisation of ₹3.82 lakh crores, the company demonstrated robust operational momentum as net sales climbed to ₹15,520.54 crores, marking a 7.20% quarter-on-quarter rise and 13.49% year-on-year expansion. However, the stock's muted response—trading at ₹1,595.00 with just 0.36% gains following the results—reflects investor concerns about stretched valuations at 33x trailing earnings and technical weakness, with the stock languishing 13.83% below its 52-week high of ₹1,850.95.
Sun Pharmaceutical Industries Ltd is Rated Hold
Sun Pharmaceutical Industries Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 19 January 2026. While the rating was revised on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 31 January 2026, providing investors with the most up-to-date view of the company’s fundamentals and market performance.
Sun Pharmaceutical Industries Ltd: Navigating Challenges Amidst Nifty 50 Membership
Sun Pharmaceutical Industries Ltd, a stalwart in the Pharmaceuticals & Biotechnology sector and a key constituent of the Nifty 50 index, is currently facing a challenging phase marked by subdued price performance and a recent downgrade in its mojo rating. Despite its large-cap status and significant market presence, the stock’s recent trends highlight the complexities of maintaining benchmark relevance amid evolving market dynamics and sectoral pressures.
Sun Pharmaceutical Industries Ltd: Navigating Challenges Amidst Nifty 50 Membership
Sun Pharmaceutical Industries Ltd, a key constituent of the Nifty 50 index, is navigating a challenging phase marked by subdued price performance and a recent downgrade in its investment grade. Despite its large-cap status and significant market presence in the Pharmaceuticals & Biotechnology sector, the stock has underperformed the broader market benchmarks, reflecting evolving investor sentiment and institutional holding dynamics.
Sun Pharmaceutical Industries Ltd: Navigating Challenges as a Nifty 50 Constituent
Sun Pharmaceutical Industries Ltd, a stalwart in the Pharmaceuticals & Biotechnology sector and a key constituent of the Nifty 50 index, has recently experienced a recalibration in its market standing. Despite its large-cap status and significant institutional interest, the stock has faced headwinds reflected in its recent performance and a downgrade in its Mojo Grade from Buy to Hold. This article analyses the implications of its Nifty 50 membership, institutional holding dynamics, and the broader impact on investor sentiment and benchmark relevance.
Sun Pharmaceutical Industries Sees Notable Surge in Derivatives Open Interest Amid Mixed Price Action
Sun Pharmaceutical Industries Ltd has witnessed a notable 11.16% increase in open interest in its derivatives segment, signalling heightened market activity and shifting investor positioning. Despite this surge, the stock’s price performance remains subdued, trading below key moving averages and reflecting cautious sentiment amid broader sector and market trends.
Sun Pharmaceutical Industries Ltd: Navigating Nifty 50 Membership and Market Dynamics
Sun Pharmaceutical Industries Ltd, a stalwart in the Pharmaceuticals & Biotechnology sector, continues to command attention as a key constituent of the Nifty 50 index. Despite recent challenges reflected in its performance metrics and a recent downgrade in its Mojo Grade, the company’s large-cap status and institutional interest underscore its enduring significance in India’s benchmark equity index.
Sun Pharmaceutical Industries Ltd Falls 2.25%: 6 Key Factors Driving the Weekly Decline
Sun Pharmaceutical Industries Ltd closed the week at Rs.1,631.65, down 2.25% from the previous Friday’s close of Rs.1,669.20, while the Sensex declined 3.31% over the same period. Despite the stock’s weekly loss, it outperformed the broader market benchmark by 1.06 percentage points amid mixed technical signals, heightened derivatives activity, and a downgrade to a Hold rating by MarketsMOJO. This review analyses the key events shaping the stock’s performance during the week ending 23 January 2026.
Sun Pharmaceutical Industries Sees Sharp Open Interest Surge Amid Mixed Technical Signals
Sun Pharmaceutical Industries Ltd has witnessed a notable 15.5% surge in open interest in its derivatives segment, signalling increased market participation and potential shifts in investor positioning. Despite this, the stock trades below all major moving averages, reflecting a complex technical backdrop as investors weigh directional bets amid subdued delivery volumes and sector headwinds.
Sun Pharmaceutical Industries Sees Notable Surge in Derivatives Open Interest Amid Mixed Price Signals
Sun Pharmaceutical Industries Ltd has witnessed a significant increase in open interest in its derivatives segment, signalling heightened market activity and evolving investor positioning. Despite a modest price gain, the stock trades below key moving averages, reflecting a complex interplay of bullish and cautious sentiments among traders.
Sun Pharmaceutical Industries Sees Notable Surge in Derivatives Open Interest Amid Mixed Technical Signals
Sun Pharmaceutical Industries Ltd (SUNPHARMA) has witnessed a notable 10.55% increase in open interest (OI) in its derivatives segment, signalling heightened market activity and shifting positioning among traders. Despite this surge, the stock trades below all major moving averages, reflecting a complex technical backdrop as investors weigh directional bets amid subdued delivery volumes and mixed sector performance.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
